

## PF-PTD-141

## Free Light Chains



	Accredited to ISO 15189:2012
Synonyms	FLC
Clinical Indication	Investigation and monitoring of B cell dyscrasias, especially light chain only myeloma, MGUS, amyloid.
	Serum Free Light Chains have a role in the diagnosis of primary systemic amyloidosis (AL) with up to 98% of patients demonstrating abnormal levels.
	Because of their shorter half-life, FLC may show a quicker response to treatment then intact immunoglobulin.
	Further investigation of an abnormal band in serum.
Part of Profile / See Also	
Request Form	Combined Pathology manual Blood form or ICE request
Availability / Frequency of	Analysed if specific criteria met
Analysis	Minimum retesting interval is 3 months, 2 weeks for haematology.
Turnaround Time	One week.
Patient Preparation	None required.
Sample Requirements	
Specimen Type	Serum
Volume	2 ml



Gold-top (SST) tube (preferred)

Plain serum or lithium heparin samples may also be used

Reference Range & Units	Serum kappa FLC 3.3 – 19.4 mg/L
	Serum lambda FLC 5.7 – 26.3 mg/L
	Kappa/lambda ratio 0.26 – 1.65
	Renal impairment reduced FLC clearance. Renal reference range for FLC ratio is 0.37 – 3.10
Interferences	
Interpretation & Clinical	Increased levels may be seen with raised polyclonal immunoglobulin, and in
Decision Value (if applicable)	renal impairment. Abnormal ratio indicates B cell dyscrasia.

Container



## PF-PTD-141

Antigen excess causes all immunoassays to underestimate very high levels of antigen. Free-lite assays are manufactured to minimise antigen excess, but it is not possible to completely eradicate it. Free-lite results should be interpreted in conjunction with other laboratory tests and clinical history.

## References

Test code

FLC

Lab Handling

Aliquot and store at 4°C